I5Q-MC-CGAT:A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505835-11-00

Acronym

I5Q-MC-CGAT

Enrollment

Registered

2023-11-20

Start date

2021-03-12

Completion date

Unknown

Last updated

2025-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Migraine

Brief summary

Change from Baseline in the Number of Monthly Migraine Headache Days [Time Frame: Baseline, 3 Months]

Interventions

DRUGGalcanezumab

DRUGPlacebo to match LY2951742

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Change from Baseline in the Number of Monthly Migraine Headache Days [Time Frame: Baseline, 3 Months]	—

Countries

Denmark, France, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026